Frederick Lief Ruberg, MD

Associate Professor, Medicine

Frederick Ruberg
617.638.8968
75 E. Newton St Collamore Building

Biography

Dr. Ruberg’s clinical and research expertise is in the field of cardiac imaging including echocardiography and cardiovascular magnetic resonance imaging (CMR). Dr. Ruberg applies imaging in research designed to facilitate improved diagnosis and management of the infiltrative cardiomyopathy cardiac amyloidosis.

Other Positions

  • Associate Professor, Radiology, Boston University Chobanian & Avedisian School of Medicine
  • Member, Whitaker Cardiovascular Institute, Boston University
  • Member, Amyloidosis Center, Boston University
  • Program Director, Pilot Translational & Clinical Studies Program, Clinical and Translational Science Institute, Boston University Chobanian & Avedisian School of Medicine

Education

  • University of Pennsylvania School of Medicine, MD
  • Haverford College, BA

Publications

  • Published on 1/31/2023

    Staron A, Mendelson LM, Joshi T, Ruberg FL, Sanchorawala V. Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre. Amyloid. 2023 Jan 31; 1-6. PMID: 36718932.

    Read at: PubMed
  • Published on 1/14/2023

    Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, Dember LM, Frantz JG, Hershberger RE, Maurer MS, Nativi-Nicolau J, Sanchorawala V, Sheikh FH. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 Jan 14. PMID: 36697326.

    Read at: PubMed
  • Published on 12/21/2022

    Ruberg FL, Baggish AL, Hays AG, Jerosch-Herold M, Kim J, Ordovas KG, Reddy G, Shenoy C, Weinsaft JW, Woodard PK. Utilization of cardiovascular magnetic resonance (CMR) imaging for resumption of athletic activities following COVID-19 infection: an expert consensus document on behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention (CVRI) Leadership and endorsed by the Society for Cardiovascular Magnetic Resonance (SCMR). J Cardiovasc Magn Reson. 2022 Dec 21; 24(1):73. PMID: 36539786.

    Read at: PubMed
  • Published on 12/21/2022

    Ruberg FL, Baggish AL, Hays AG, Jerosch-Herold M, Kim J, Ordovas KG, Reddy G, Shenoy C, Weinsaft JW, Woodard PK. Utilization of Cardiovascular Magnetic Resonance Imaging for Resumption of Athletic Activities Following COVID-19 Infection: An Expert Consensus Document on Behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention Leadership and Endorsed by the Society for Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2023 Jan; 16(1):e014106. PMID: 36541203.

    Read at: PubMed
  • Published on 11/30/2022

    Rowin EJ, Ruberg FL, Das G, Higgins D, Lipe WC, Bokhari N, Dehn M, Maron BJ, Maron MS. Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2022 Dec; 15(12):e014938. PMID: 36448453.

    Read at: PubMed
  • Published on 11/15/2022

    Cuddy SA, Datar Y, Ovsak G, Saith S, Murphy SP, Bay CP, Haddad M, Lilleness B, Muralidhar V, Pipilas A, Vuong J, Guardino E, Maurer MS, Ruberg FL, Falk RH, Dorbala S. Optimal Echocardiographic Parameters to Improve the Diagnostic Yield of Tc-99m-Bone Avid Tracer Cardiac Scintigraphy for Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2022 Nov; 15(11):e014645. PMID: 36378779.

    Read at: PubMed
  • Published on 11/15/2022

    Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Grogan M, Witteles R, Ruberg FL, Maurer MS, Tran N, Qin X, Vasey SY, Weiss BM, Vermeulen J, Jaccard A. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. JACC CardioOncol. 2022 Nov; 4(4):474-487. PMID: 36444227.

    Read at: PubMed
  • Published on 8/24/2022

    Alreshq R, Cozzolino M, Lilleness B, Pipilas A, Mendelson L, Joshi T, Muralidhar V, Guardino E, Berk JL, Siddiqi OK, Gopal DM, Sanchorawala V, Ruberg FL. Light Chain Testing Abnormalities Among Patients With Transthyretin Amyloid Cardiomyopathy Referred for Technetium-99m Pyrophosphate Imaging. Am J Cardiol. 2022 Oct 15; 181:105-112. PMID: 36028388.

    Read at: PubMed
  • Published on 8/22/2022

    Tahir UA, Katz DH, Avila-Pachecho J, Bick AG, Pampana A, Robbins JM, Yu Z, Chen ZZ, Benson MD, Cruz DE, Ngo D, Deng S, Shi X, Zheng S, Eisman AS, Farrell L, Hall ME, Correa A, Tracy RP, Durda P, Taylor KD, Liu Y, Johnson WC, Guo X, Yao J, Chen YI, Manichaikul AW, Ruberg FL, Blaner WS, Jain D, Bouchard C, Sarzynski MA, Rich SS, Rotter JI, Wang TJ, Wilson JG, Clish CB, Natarajan P, Gerszten RE. Whole Genome Association Study of the Plasma Metabolome Identifies Metabolites Linked to Cardiometabolic Disease in Black Individuals. Nat Commun. 2022 08 22; 13(1):4923. PMID: 35995766.

    Read at: PubMed
  • Published on 7/19/2022

    Schwartz B, Schou M, Ruberg FL, Rucker D, Choi J, Siddiqi O, Monahan K, Køber L, Gislason G, Torp-Pedersen C, Andersson C. Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study. JACC CardioOncol. 2022 Sep; 4(3):313-322. PMID: 36213365.

    Read at: PubMed

View 103 more publications: View full profile at BUMC

View all profiles